Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 25, 2021

Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells

Aguslina Kirtishanti, Siswandono Siswodihardjo, I Ketut Sudiana, Desak G. A. Suprabawati and Aristika Dinaryanti



Human epidermal growth factor receptor type 2 (HER2)-expressing breast cancer patients indicate poor prognosis in disease progression. HER2 overexpression can increase activities of Ras-mitogen activated protein kinase (Ras-MAPK) pathway and Janus Kinase (JAK)-STAT3, increasing breast cancer cell proliferation as demonstrated by marker Ki67. Therapeutic options for HER2-expressing breast cancer are limited and have major side effects, so anticancer development as an antiproliferative is needed. From previous research, synthetic chemical 4-(tert-butyl)-N-carbamoylbenzamide (4TBCB) compound has cytotoxic activity in vitro on HER2-expressing breast cancer cells. This study wanted to determine the mechanism 4TBCB compound in inhibiting HER2 signaling through Rat Sarcoma (Ras) and signal transducer and activator of transcription 3 (STAT3) pathway in HER2-expressing breast cancer cells.


Breast cancer cells were isolated from the biopsy tissue of breast cancer patients. The isolated cells were cultured and given 4TBCB test compound with three concentrations (0.305, 0.61, and 1.22 mM) and lapatinib 0.05 mM as a comparison compound. Cancer cell cultures were stained with monoclonal antibodies phosphorylated HER2 (pHER2), phosphorylated Ras (pRas), phosphorylated STAT3 (pSTAT3), and Ki67. The expression of pHER2, pRas, pSTAT3, and Ki67 proteins was observed using the immunofluorescence method and the results were compared with control cells, namely cancer cells that were not given 4TBCB and lapatinib but stained with monoclonal antibodies.


4TBCB compounds (0.61 and 1.22 mM) and lapatinib can reduce pHER2, pRas, pSTAT3, and Ki67 expressions compared to control cells.


4TBCB compounds (0.61 and 1.22 mM) can reduce pHER2, pRas, pSTAT3, Ki67 expressions and predicted to inhibit HER2 signaling through the Ras and STAT3 pathways in HER2-expressing breast cancer cells.

Corresponding author: Siswandono Siswodihardjo, Department of Medicinal Chemistry, Faculty of Pharmacy, University of Airlangga, Surabaya, Indonesia, Phone: +62 8123206328, E-mail:

Funding source: Directorate General of Resources for Science, Technology and Higher Education of Ministry of Research, Technology and Higher Education (KEMENRISTEK DIKTI)


We acknowledge Eryk Hendrianto and Aida Ariyanti from the Stem Cell Research Center for supporting the current research.

  1. Research funding: Directorate General of Resources for Science, Technology and Higher Education of Ministry of Research, Technology and Higher Education (KEMRISTEK DIKTI).

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Research involving human subjects complied with all relevant national regulations, institutional policies and is in accordance with the tenets of the Helsinki Declaration (as revised in 2013), and has been approved by Ethical Commission of General Hospital in Surabaya, Indonesia.


1. International Agency for Research on Cancer, World Health Organization. Available from: [Accessed 18 Nov 2019].Search in Google Scholar

2. Li, HQ, Yan, T, Yang, Y, Shi, L, Zhou, CF, Zhu, HL. Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N′-phenylureas and thioureas as antitumor agents. Bioorg Med Chem 2010;18:305–13. in Google Scholar

3. Adamczyk, A, Grela-Wojewoda, A, Domagala-Haduch, M, Ambicka, A, Harazin-Lechowska, A, Janecka, A, et al.. Protein involved in HER2 signalling pathway, their relations and influence on metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting. J Canc 2017;8:131–9. in Google Scholar

4. Sirkisoon, SR, Carpenter, RL, Rimkus, T, Miller, L, Barlow, LM, Lo, HW. EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci (Elite Ed) 2016;8:245–63.10.2741/e765Search in Google Scholar

5. Igbal, N, Igbal, N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014;2014:1–9.10.1155/2014/852748Search in Google Scholar PubMed PubMed Central

6. Shah, D, Osipo, C. Cancer stem cells and HER2 positive breast cancer: the story so far. Gene Dis 2016;3:114–23. in Google Scholar

7. Eckert, LB, Repasky, GA, Ulku, AS, McFall, A, Zhou, H, Sartor, CI, et al.. Involvement of ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004;64:4585–92. in Google Scholar

8. Zhang, W, Liu, HT. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res 2002;12:9–18. in Google Scholar

9. Scaltriti, M, Baselga, J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Canc Res 2006;12:5268–72. in Google Scholar

10. Chung, SS, Giehl, N, Wu, Y, Vadgama, JV. STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol 2014;44:403–11. in Google Scholar

11. Ragab, HM, Samy, N, Afify, M, Maksoud, NAE, Shaaban, HM. Assessment of Ki-67 as a potential biomarker in patients with breast cancer. J Genet Eng Biotechnol 2018;16:479–84. in Google Scholar

12. D’Amato, V, Raimondo, L, Formisano, L, Giuliano, M, Placido, SD, Rosa, R, et al.. Mechanism of lapatinib resistance in HER2-driven breast cancer. Canc Treat Rev 2015;41:877–83.10.1016/j.ctrv.2015.08.001Search in Google Scholar PubMed

13. Eustace, AJ, Conlon, NT, McDermott, MSJ, Browne, BC, O’Leary, P, Holmes, FA, et al.. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and trail. BMC Canc 2018;18:965. in Google Scholar

14. Kesuma, D, Siswandono, Purwanto, BT, Rudyanto, M. Synthesis of N-(phenylcarbamothioyl)-benzamide derivatives and their cytotoxic activity against MCF-7 cells. J Chin Pharm Sci 2018;27:696–702.10.5246/jcps.2018.10.071Search in Google Scholar

15. Widiandani, T, Arifianti, L, Siswandono. Docking, synthesis and cytotoxicity test on human breast cancer cell line (T47D) of N-(allylcarbamothioyl)benzamide. IJPCR 2016;8:372–6.Search in Google Scholar

16. Kirtishanti, A, Siswandono, S, Sudiana, IK. Synthesis and cytotoxic activity of N-(4-bromo)-benzoyl-N′-phenylthiourea and 4-(tert-butyl)-N-carbamoylbenzamide on primary cells of HER2-positive breast cancer. Res J Pharm Technol 2021;14:1195–200.10.5958/0974-360X.2021.00213.4Search in Google Scholar

17. Dinaryanti, A, Karsari, D, Ertanti, N, Ihsan, I, Ariyanti, A, Rantam, FA, et al.. Isolation and characterization of skin derived mesenchymal stem cell (SMSCs) from New Zealand rabbit, Oryctolagus cuniculus: a in vitro study. Biochem Cell Arch 2019;19:4797–801.Search in Google Scholar

18. Handala, L, Fiore, T, Rouille, Y, Helle, F. QuantIF: an imageJ macro to automatically determine the percentage of infected cells after immunofluorescence. Viruses 2019;11:165. in Google Scholar

19. Jensen, EC. Quantitative analysis of histological staining and fluorescence using imageJ. Anat Rec 2013;296:378–81. in Google Scholar

20. Jing, X, Cui, X, Liang, H, Hao, C, Yang, Z, Li, X, et al.. CD24 is a potential biomarker for prognosis in human breast carcinoma. Cell Physiol Biochem 2018;48:111–9. in Google Scholar

21. Lobba, ARM, Forni, MF, Carreira, ACO, Sogayar, MC. Differential Expression of CD90 and CD14 stem cell markers in malignant breast cancer cell lines. Cytometry 2012;81A:1084–91. in Google Scholar

22. Siswandono. Medicinal chemistry, 2nd ed. Surabaya: Airlangga University Press; 2016:417–38, 447–51 pp.Search in Google Scholar

23. Simanshu, DK, Nissley, DV, McCormick, F. RAS proteins and their regulators in human disease. Cell 2017;170:17–33. in Google Scholar

24. Asati, V, Mahapatra, DK, Bharti, SK. K-Ras and its inhibitors towards personalized cancer treatment : pharmacological and structural perspectives. Eur J Med Chem 2017;125:299–314. in Google Scholar

25. Sudiana, IK. Pathobiology of molecular cancer. Jakarta: Salemba Medika; 2011:53–60 p.Search in Google Scholar

26. Banerjee, K, Resat, J. Constitutive activation of STAT3 in breast cancer cells: a review. Int J Canc 2016;138:2570–8. in Google Scholar

27. Hashmi, AA, Hashmi, KA, Irfan, M, Khan, SM, Edhi, MM, Ali, JP, et al.. Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. BMC Res Notes 2019;12:605. in Google Scholar

28. Segovia-Mendoza, M, Gonzalez-Gonzalez, ME, Barrera, D, Diaz, L, Garcia-Becerra, R. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinb in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Am J Cancer Res 2015;5:2531–61.Search in Google Scholar

29. Carpenter, RL, Lo, H. STAT3 target genes relevant to human cancers. Cancers 2014;6:897–925. in Google Scholar

30. Leslie, K, Lang, C, Devgan, G, Azare, J, Berishaj, M, Gerald, W, et al.. Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 2006;66:2544–53. in Google Scholar

Received: 2020-12-14
Accepted: 2021-03-24
Published Online: 2021-06-25

© 2021 Walter de Gruyter GmbH, Berlin/Boston